New Products, Philanthropic Initiative, Approved Acquisitions, and Pipeline Developments Boost Growth - Research Report on Mylan, UnitedHealth, GSK, Actavis, and Mallinckrodt
NEW YORK, September 13, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Mylan Inc. (NASDAQ: MYL), UnitedHealth Group Inc. (NYSE: UNH), GlaxoSmithKline plc (ADR) (NYSE: GSK), Actavis Inc. (NYSE: ACT), and Mallinckrodt plc (NYSE: MNK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Mylan Inc. Research Report
On September 9, 2013, Mylan Inc.'s subsidiary Mylan Specialty L.P. (Mylan Specialty) announced that its Get Schooled in Anaphylaxis initiative has launched a new tool, a children's e-book narrated by Emmy-award winning actress Julie Bowen, to help raise awareness and preparedness for life-threatening allergic reactions or anaphylaxis. According to Mylan Specialty, the e-book, titled The Adventures of Ana and Phyl: The Carnival, is designed to assist parents and elementary school staff talk to kids about this sometimes scary subject in a non-threatening way. According to the Company, the e-book was partly inspired by the many submissions received through the Get Schooled in Anaphylaxis Challenge Competition that culminated earlier in 2013, and is dedicated to the 15 scholarship winners and honors them by naming the characters after them. The Company further stated that interested parties can get the e-book for free at the Get Schooled in Anaphylaxis website. The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5a20_MYL]
--
UnitedHealth Group Inc. Research Report
On September 5, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that employees of Arizona Diamondbacks have joined the Company to stuff backpacks with food to support Kitchen on the Street's Bags of Hope Program, a childhood hunger program. According to the Company, both the organizations are working together to help Arizona-based nonprofit feed nearly 700 children in September 2013. UnitedHealth added that the project is the latest "Do Good. Live Well." employee volunteer initiative, whose mission is to prevent hunger and obesity, inspire service, and encourage volunteerism in communities where UnitedHealth employees live and work. Jeri Jones, west region president, UnitedHealthcare Community & State, said, "We are grateful for the opportunity to partner with the Diamondbacks and Kitchen on the Street to help build a healthier community and provide Phoenix-area children access to nutritious food." The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]
--
GlaxoSmithKline plc (ADR) Research Report
On September 10, 2013, GlaxoSmithKline plc (GSK) and Theravance Inc. (Theravance) announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) has recommended approval of umeclidinium/vilanterol in US, for treating the patients with chronic obstructive pulmonary disease (COPD), including bronchitis and emphysema. The Company stated that majority of the advisory committee members are of the opinion that the safety of the investigational medicine has been adequately demonstrated at the 62.5/25mcg dose for the proposed indication and the efficacy data provided substantial evidence of a clinically meaningful benefit for UMEC/VI 62.5/25mcg once daily for the long-term, maintenance treatment of airflow obstruction in COPD. The Full Research Report on GlaxoSmithKline plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2a35_GSK]
--
Actavis Inc. Research Report
On September 10, 2013, Actavis Inc. (Actavis) and Warner Chilcott plc (Warner Chilcott) announced that shareholders of both the Companies have approved a proposal regarding Actavis' acquisition of Warner Chilcott. According to Actavis, the Company and Warner Chilcott's shareholder approvals fulfills certain conditions for closing of the transaction, which expected to occur early in Q4 2013, subject to certain regulatory approvals, approval by the Irish High Court and the customary closing conditions. The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]
--
Mallinckrodt plc Research Report
On September 5, 2013, Mallinckrodt plc (Mallinckrodt) presented the results of its efficacy study on MNK-795 - its investigational, extended-release oral formulation of oxycodone and acetaminophen, at PAINWeek - a national conference on pain for frontline practitioners, held in Las Vegas through September 4 to September 7, 2013. According to the Company, investigational drug MNK-795 achieved the primary endpoint in a Phase 3 efficacy trial in the treatment of acute pain following bunionectomy. Mallinckrodt stated that in the study, MNK-795 showed statistically significant improvement in pain scores compared to placebo from baseline over 48 hours. Tom Smith, MD, Chief Medical Officer at Mallinckrodt, said, "We are pleased that MNK-795 met the primary endpoint of the study and we are excited to be able to share the clinical story for this product by presenting these and other data at PAINWeek." The Full Research Report on Mallinckrodt plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/24f6_MNK]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Analysts' Corner
Share this article